Prospective Study on Plasma Pro-endothelin-1 in Predicting Bronchopulmonary Dysplasia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01644981

Enrollment

110

Registered

2012-07-19

Start date

2012-05-31

Completion date

2013-12-31

Last updated

2016-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary Dysplasia

Brief summary

Serial quantitative measurements of plasma pro-endothelin-1 concentrations in very preterm infants. Comparing pro-endothelin-1 with established clinical indices of bronchopulmonary dysplasia (BPD). Hypothesis: Pulmonary-vascular remodeling in infants developing BPD is directly related to circulating pro-endothelin-1, which therefore serves as surrogate marker of BPD.

Interventions

OTHERblood sampling

blood sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Weeks to 4 Months

Healthy volunteers

Yes

Inclusion criteria

* Very preterm infants born before 32 weeks gestational age

Exclusion criteria

* Severe fetal malformation, congenital heart defect, inborn syndrome, cardiomyopathy, fetal hydrops

Design outcomes

Primary

Measure	Time frame	Description
duration of supplemental oxygen requirement	36 weeks postmenstrual age	Bronchopulmonary dysplasia

Secondary

Measure	Time frame	Description
duration of respiratory pressure support	during hospitalisation	respiratory pressure support either mechanical and/or nCPAP (days)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026